Successful Treatment of Steroid-Dependent Severe Eosinophilic Pneumonia With Benralizumab: A Case Report.
Takeru Ichikawa, Yuki Takigawa, Keiichi Fujiwara, Tomoyoshi Inoue, Shoichiro Matsumoto, Keisuke Shiraha, Mayu Goda, Suzuka Matsuoka, Hiromi Watanabe, Kenichiro Kudo, Akiko Sato, Ken Sato, Takuo Shibayama
Abstract
Open AccessEosinophilic pneumonia (EP) often requires long-term steroid treatment, which has adverse effects. We report the case of an 83-year-old male with minimal-change nephrotic syndrome, refractory asthma and steroid-induced diabetes who developed a severe steroid-dependent EP relapse during steroid tapering. Considering his age, comorbidities and steroid dependency, treatment with benralizumab, an anti-interleukin-5 receptor antibody, was initiated. Benralizumab rapidly depleted eosinophils, leading to significant clinical and radiological improvements, allowing successful sustained tapering of prednisolone to 5 mg daily, and improving diabetes control without EP relapse. Benralizumab provides effective steroid-sparing therapy for steroid-dependent EP, particularly in complex patients.